Lipum AB
Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. The company develops SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. It has a collaboration with NorthXBiologies for production of SOL-116 setatt; and a… Read more
Lipum AB (LIPUM) - Net Assets
Latest net assets as of December 2025: Skr-4.74 Million SEK
Based on the latest financial reports, Lipum AB (LIPUM) has net assets worth Skr-4.74 Million SEK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr6.88 Million) and total liabilities (Skr11.63 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr-4.74 Million |
| % of Total Assets | -68.87% |
| Annual Growth Rate | N/A |
| 5-Year Change | -117.01% |
| 10-Year Change | N/A |
| Growth Volatility | 2778.87 |
Lipum AB - Net Assets Trend (2017–2025)
This chart illustrates how Lipum AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Lipum AB (2017–2025)
The table below shows the annual net assets of Lipum AB from 2017 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr-4.74 Million | -121.56% |
| 2024-12-31 | Skr22.00 Million | +381.10% |
| 2023-12-31 | Skr4.57 Million | -83.70% |
| 2022-12-31 | Skr28.05 Million | +0.60% |
| 2021-12-31 | Skr27.88 Million | +763.91% |
| 2020-12-31 | Skr3.23 Million | -79.66% |
| 2019-12-31 | Skr15.87 Million | +8465.74% |
| 2018-12-31 | Skr185.26K | -92.77% |
| 2017-12-31 | Skr2.56 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lipum AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 28713585600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr49.68 Million | % |
| Other Components | Skr235.74 Million | % |
| Total Equity | Skr-4.74 Million | 100.00% |
Lipum AB Competitors by Market Cap
The table below lists competitors of Lipum AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nureca Limited
NSE:NURECA
|
$7.85 Million |
|
Equites Property Fund Ltd
JSE:EQU
|
$7.85 Million |
|
Profusa, Inc. Common Stock
NASDAQ:PFSA
|
$7.85 Million |
|
PARKER-HANNIFIN CO. - Dusseldorf Stock Exchang
DU:PAR
|
$7.85 Million |
|
PIONEER MEDIA HOLDINGS
F:6NU
|
$7.84 Million |
|
Noble Helium Ltd
AU:NHE
|
$7.84 Million |
|
Levinstein Eng
TA:LEVI
|
$7.84 Million |
|
Noble Finance Company
PINK:NBLWF
|
$7.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lipum AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 21,996,000 to -4,742,000, a change of -26,738,000 (-121.6%).
- Net loss of 71,526,000 reduced equity.
- New share issuances of 408,000 increased equity.
- Other factors increased equity by 44,380,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-71.53 Million | -1508.35% |
| Share Issuances | Skr408.00K | +8.6% |
| Other Changes | Skr44.38 Million | +935.89% |
| Total Change | Skr- | -121.56% |
Book Value vs Market Value Analysis
This analysis compares Lipum AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | Skr1234.63 | Skr14.25 | x |
| 2018-12-31 | Skr89.28 | Skr14.25 | x |
| 2019-12-31 | Skr3.35 | Skr14.25 | x |
| 2020-12-31 | Skr0.64 | Skr14.25 | x |
| 2021-12-31 | Skr6.71 | Skr14.25 | x |
| 2022-12-31 | Skr4.41 | Skr14.25 | x |
| 2023-12-31 | Skr0.55 | Skr14.25 | x |
| 2024-12-31 | Skr1.28 | Skr14.25 | x |
| 2025-12-31 | Skr-0.22 | Skr14.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lipum AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-233.88%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -0.09% | -14236.57% | 0.00x | 1.17x | Skr-258.47K |
| 2018 | -1.31% | -89.05% | 0.00x | 49.37x | Skr-20.94K |
| 2019 | -58.71% | -23851.30% | 0.00x | 1.11x | Skr-10.90 Million |
| 2020 | -654.96% | -142791.41% | 0.00x | 3.13x | Skr-21.46 Million |
| 2021 | -187.96% | 0.00% | 0.00x | 1.78x | Skr-55.19 Million |
| 2022 | -136.36% | 0.00% | 0.00x | 1.23x | Skr-41.05 Million |
| 2023 | -813.17% | -70147.17% | 0.00x | 2.65x | Skr-37.64 Million |
| 2024 | -252.39% | 0.00% | 0.00x | 2.07x | Skr-57.72 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | Skr-71.05 Million |
Industry Comparison
This section compares Lipum AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lipum AB (LIPUM) | Skr-4.74 Million | -0.09% | N/A | $7.85 Million |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |